Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

Heritage Bio Labs

Research Library

Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.

Browse by productGeneral topics

Find articles

All articles

Showing 385–396 of 411 articles

  • Understand the science

    How a pragmatic trial studies tirzepatide in everyday care

    Tirzepatide is a GIP and GLP-1 receptor agonist peptide. The “GLP-2” in this catalog label does not identify a receptor it activates. In 2026, the SURMOUNT-REAL UK investigators published a plan to assess how offering tirzepatide would affect outcomes in a routine primary care setting.

    TIRZ GLP-22 sources (2022, 2026)

  • Check methods and identity

    How sleep and weight measurements related to blood pressure

    Tirzepatide acts at GIP and GLP-1 receptors, regardless of the “GLP-2” wording used in the catalog. A 2026 analysis of the SURMOUNT-OSA trials examined how changes in sleep apnea measurements and weight were related to changes in cardiovascular risk markers.

    TIRZ GLP-22 sources (2024, 2026)

  • Explore study findings

    What researchers observed after tirzepatide withdrawal

    Tirzepatide is a GIP and GLP-1 receptor agonist peptide. The “TIRZ GLP-2” label identifies the catalog entry. In a later analysis of SURMOUNT-4, researchers examined how weight regain after withdrawal related to changes in blood pressure, waist circumference and other measures.

    TIRZ GLP-22 sources (2022, 2025)

  • Explore study findings

    What a myostatin antibody study tells us about its own target

    Tirzepatide is a peptide that activates the GIP and GLP-1 receptors. IGF-1 LR3 is an engineered, extended insulin-like growth factor protein. A 2026 trial added a different molecule to tirzepatide, the antibody apitegromab.

    TIRZ / IGF-1 LR33 sources (1992, 2026)

  • Check methods and identity

    Why two compounds given together and a single formulation are separate questions

    Tirzepatide is a GIP and GLP-1 receptor agonist peptide. IGF-1 LR3 is a modified version of the growth-factor protein IGF-1. Studies registered for tirzepatide with a different molecule illustrate why the preparation is part of what researchers have to define.

    TIRZ / IGF-1 LR33 sources (2023–2026)

  • Interpret the evidence

    What basal insulin studies tell us about the limits of an add-on result

    Tirzepatide activates GIP and GLP-1 receptors. IGF-1 LR3 is a modified insulin-like growth factor protein. A 2026 analysis examined tirzepatide added to basal insulin and shows why an add-on result has to be read with the exact background treatment in view.

    TIRZ / IGF-1 LR33 sources (2023, 2026)

  • Check methods and identity

    How an assay separates intact IGF-1 LR3 from its breakdown products

    Tirzepatide is a peptide that activates GIP and GLP-1 receptors, while IGF-1 LR3 is an engineered growth-factor protein. Older research developed a way to distinguish the intact growth-factor analog from related molecules and some of its breakdown products.

    TIRZ / IGF-1 LR32 sources (2021, 2026)

  • Interpret the evidence

    What a digestion experiment can tell us about an IGF-1 LR3 variant

    Tirzepatide is a GIP and GLP-1 receptor agonist peptide. IGF-1 LR3 is a modified, extended growth-factor protein. An older study investigated which changes to LR3 made the resulting molecules more resistant to a digestive enzyme. The researchers tested purified pepsin from pigs in the laboratory.

    TIRZ / IGF-1 LR32 sources (1996, 2026)

  • Check methods and identity

    Why studies measure food intake separately from body weight

    Tirzepatide activates GIP and GLP-1 receptors. IGF-1 LR3 is an engineered, extended version of insulin-like growth factor 1. Older direct experiments on each component help explain why a study of the pair would need to measure food intake separately from weight and tissue outcomes.

    TIRZ / IGF-1 LR32 sources (1997, 2025)

  • Check methods and identity

    What the COURAGE MRI substudy measured in the thigh

    Trevogrumab is an investigational monoclonal antibody, a large protein engineered to block myostatin, also called GDF8. In 2026, the COURAGE trial sponsor reported an MRI substudy that asked whether adding this antibody to semaglutide changed thigh muscle volume.

    Trevogrumab3 sources (2024–2026)

  • Interpret the evidence

    Why COURAGE reported lean mass and weight separately at 52 weeks

    Trevogrumab is a larger protein called a monoclonal antibody, designed to block the muscle growth regulator myostatin. The 2026 sponsor report from COURAGE compared changes on the scale with changes in whole-body lean mass when the investigational antibody was added to semaglutide.

    Trevogrumab2 sources (2024, 2026)

  • Understand the science

    How researchers defined low lean mass at the start of COURAGE

    Trevogrumab is a larger protein antibody that targets myostatin, a regulator of muscle mass. Investigators studied the antibody with semaglutide and examined whether the lean mass results differed in adults who entered the trial with low lean mass.

    Trevogrumab2 sources (2024, 2026)

Browse by product

General topics

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Library index (JSON)